BioCardia, Inc. (BCDA): Total Assets
$3.41M
As of 2025-12-31
$4.75M
As of 2026-06-30
-29.6%
3-year compound annual growth
-32.0%
5-year compound annual growth
-3.5%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.41M | -8.4% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $3.72M | +24.7% | 2026-03-24, Balance as of period end |
| 2023-12-31 | $2.99M | -69.5% | 2025-03-26, Balance as of period end |
| 2022-12-31 | $9.79M | -37.7% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $15.72M | -32.9% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $23.42M | +205.1% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $7.68M | +19.7% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $6.42M | -52.6% | 2020-04-09, Balance as of period end |
| 2017-12-31 | $13.54M | -38.7% | 2019-04-02, Balance as of period end |
| 2016-12-31 | $22.08M | +354.2% | 2018-03-16, Balance as of period end |
| 2015-12-31 | $4.86M | -65.0% | 2017-03-30, Balance as of period end |
| 2014-12-31 | $13.88M | n/c | 2016-03-25, Balance as of period end |
| 2013-12-31 | $13.54M | n/c | 2015-03-24, Balance as of period end |
| 2012-12-31 | $13.30M | -3.2% | 2014-03-24, Balance as of period end |
| 2011-12-31 | $13.73M | +152.7% | 2013-03-22, Balance as of period end |
| 2010-12-31 | $5.43M | n/a | 2012-03-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | 2025-12-31 | $3.41M | -8.4% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Amgen Inc (AMGN) | 2025-12-31 | $90.59B | -1.4% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Biogen Inc. (BIIB) | 2025-12-31 | $29.44B | +5.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $59.02B | 0.0% |
Compare BCDA, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗